ELDN - Company ID 0001404281
The table below shows Eledon Pharmaceuticals, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.80M | $6.15M | $3.67M | $5.74M | $8.50M | $6.75M |
| Short-term investments | $81.95M | $104.94M | $89.73M | $101.83M | $116.39M | $71.44M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $93.09M |
| $113.57M |
| $96.30M |
| $111.40M |
| $127.72M |
| $81.51M |
| Property, plant & equipment | - | - | - | - | - | - |
| Goodwill | - | - | - | - | - | - |
| Total assets | $126.09M | $146.67M | $129.86M | $144.91M | $161.31M | $114.58M |
| Accounts payable | $3.21M | $6.58M | $4.63M | $5.83M | $2.90M | $5.86M |
| Total current liabilities | $11.79M | $13.46M | $14.30M | $13.72M | $9.19M | $12.49M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $54.06M | $46.21M | $38.80M | $38.88M | $46.73M | $38.52M |
| Retained earnings | -$471.86M | -$440.23M | -$390.76M | -$373.30M | -$362.08M | -$310.97M |
| Total equity | $33.01M | $44.76M | $35.36M | $50.33M | $114.58M | $76.06M |